ÂÜÀòÂÒÂ×

Alicia has more than 25 years of life sciences leadership and commercial product expertise, with a particular focus on rare diseases and other areas of unmet need. Alicia currently serves as president and chief executive officer of Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases. Prior to Atalanta, Alicia served as president and chief executive officer at Juniper Pharmaceuticals, a diversified public healthcare company, where she led the successful turnaround strategy for the company resulting in a sale to Catalent in August 2018. Prior to her role at Juniper, Alicia held a number of leadership positions in the life sciences industry, including chief commercial officer at Zafgen, senior vice president and chief operating officer at Synageva BioPharma, and roles of increasing responsibility at Genzyme, including serving as vice president and general manager of the metabolic disease division, a business with multiple commercial products, including two orphan drugs. Alicia is also a member of the board of directors at GW Pharmaceuticals and the Foundation for Prader-Willi Research.

Alicia received her B.S. in health administration from the University of New Hampshire and an MBA from Northeastern University.